Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ritalin LA Will Be Novartis’ Second Marketed Once-Daily Methylphenidate

  • News

Executive Summary

Novartis' Ritalin LA will be the company's second once-daily methylphenidate formulation on the market

You may also be interested in...



Metadate CD sprinkling (correction)

Celltech's Metadate CD, like Novartis' Ritalin LA, can be sprinkled on applesauce. Celltech's once-daily methylphenidate ADHD agent received supplemental approval for applesauce sprinkling on April 9 (1"The Pink Sheet" June 10, p. 6)...

Metadate CD sprinkling (correction)

Celltech's Metadate CD, like Novartis' Ritalin LA, can be sprinkled on applesauce. Celltech's once-daily methylphenidate ADHD agent received supplemental approval for applesauce sprinkling on April 9 (1"The Pink Sheet" June 10, p. 6)...

Novartis Focalin Price Similar To Ritalin; ADHD Drug Clears FDA Nov. 13

Novartis' Focalin will be priced similarly to its parent compound Ritalin, the company said following the Nov. 13 approval of the attention deficit hyperactivity disorder drug

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS039988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By